Literature DB >> 22409561

High-dose intravenous corticosteroids for ocular inflammatory diseases.

Leon D Charkoudian1, Gui-shuang Ying, Siddharth S Pujari, Sapna Gangaputra, Jennifer E Thorne, C Stephen Foster, Douglas A Jabs, Grace A Levy-Clarke, Robert B Nussenblatt, James T Rosenbaum, Eric B Suhler, John H Kempen.   

Abstract

PURPOSE: To evaluate the effectiveness and risk of complications of high-dose intravenous pulsed corticosteroids for noninfectious ocular inflammatory diseases.
METHODS: Retrospective cohort study in which 104 eyes of 70 patients who received high-dose intravenous corticosteroids for treatment of active ocular inflammation were identified from five centers. The main outcome measures were control of inflammation and occurrence of ocular or systemic complications within 1 month after treatment.
RESULTS: Within ≤1 month of starting treatment, 57% of eyes achieved complete control of inflammation (95% confidence interval (CI): 33-83%), improving to 82% when near-complete control was included (95% CI: 61-96%). Most eyes (85%; 95% CI: 70-95%) gained clinically significant improvement in anterior chamber inflammation. One patient developed a colon perforation during treatment. No other major complications were recorded.
CONCLUSIONS: Treatment of ocular inflammation with high-dose intravenous corticosteroids resulted in substantial clinical improvement for most cases within 1 month. Complications of therapy were infrequent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409561      PMCID: PMC3306126          DOI: 10.3109/09273948.2011.646382

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  24 in total

Review 1.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

Review 2.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

3.  Causes of blindness in The Netherlands.

Authors:  J ten Doesschate
Journal:  Doc Ophthalmol       Date:  1982-01-29       Impact factor: 2.379

Review 4.  Pulsed suppressive treatment in rheumatoid arthritis: intravenous methylprednisolone and nitrogen mustard.

Authors:  T Danao; A M Segal
Journal:  J Rheumatol       Date:  1990-07       Impact factor: 4.666

5.  Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs.

Authors:  J M Piper; W A Ray; J R Daugherty; M R Griffin
Journal:  Ann Intern Med       Date:  1991-05-01       Impact factor: 25.391

6.  Acute perforation of the colon associated with chronic corticosteroid therapy.

Authors:  A L Warshaw; J P Welch; L W Ottinger
Journal:  Am J Surg       Date:  1976-04       Impact factor: 2.565

Review 7.  Uveitis: a potentially blinding disease.

Authors:  O M Durrani; C A Meads; P I Murray
Journal:  Ophthalmologica       Date:  2004 Jul-Aug       Impact factor: 3.250

8.  Intravenous pulse methylprednisolone therapy in severe inflammatory eye disease.

Authors:  D Wakefield; P McCluskey; R Penny
Journal:  Arch Ophthalmol       Date:  1986-06

9.  Methylprednisolone pulse therapy in severe anterior uveitis.

Authors:  D Wakefield
Journal:  Aust N Z J Ophthalmol       Date:  1985-11

10.  Cyclosporine for ocular inflammatory diseases.

Authors:  R Oktay Kaçmaz; John H Kempen; Craig Newcomb; Ebenezer Daniel; Sapna Gangaputra; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; Douglas A Jabs; Grace A Levy-Clarke; C Stephen Foster
Journal:  Ophthalmology       Date:  2010-01-19       Impact factor: 12.079

View more
  7 in total

Review 1.  Uveitis associated with juvenile idiopathic arthritis.

Authors:  Ethan S Sen; Andrew D Dick; Athimalaipet V Ramanan
Journal:  Nat Rev Rheumatol       Date:  2015-03-31       Impact factor: 20.543

Review 2.  Immunosuppression for the Uveitides.

Authors:  Douglas A Jabs
Journal:  Ophthalmology       Date:  2017-09-20       Impact factor: 12.079

3.  Safety of Intravenous Methylprednisolone in Refractory and Severe Pediatric Uveitis.

Authors:  Hashem H Ghoraba; Wataru Matsumiya; Hassan Khojasteh; Amir Akhavanrezayat; Irmak Karaca; Christopher Or; Negin Yavari; Sherin Lajevardi; Jaclyn Hwang; Cigdem Yasar; Diana Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2022-05-31

Review 4.  Non-Infectious Uveitis: Optimising the Therapeutic Response.

Authors:  Archana Airody; Greg Heath; Susan Lightman; Richard Gale
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

5.  Idiopathic orbital inflammation syndrome with retro-orbital involvement: a retrospective study of eight patients.

Authors:  Yumei Li; Gerald Lip; Vincent Chong; Jianhua Yuan; Zhongxiang Ding
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

Review 6.  Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review.

Authors:  Jyoti Mehta; Rajan Rolta; Brij Bhushan Mehta; Neha Kaushik; Eun Ha Choi; Nagendra Kumar Kaushik
Journal:  Front Microbiol       Date:  2022-02-15       Impact factor: 5.640

Review 7.  Juvenile idiopathic arthritis-associated uveitis.

Authors:  Sarah L N Clarke; Ethan S Sen; Athimalaipet V Ramanan
Journal:  Pediatr Rheumatol Online J       Date:  2016-04-27       Impact factor: 3.054

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.